

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on December 28, 2005.

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Examining Group 1633
Patent Application
Docket No. USF-T144X
Serial No. 10/049,502

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Maria B. Marvich, Ph.D.
Art Unit : 1633
Applicant : Said M. Sebti
Serial No. : 10/049,502
Filed : February 13, 2002
Conf. No. : 7653
For : RhoB as a Suppressor of Cancer Cell Growth and Cell Transformation

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicant has not submitted copies of the published U.S. application cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).


01/04/2006 HGUTEMA1 00000065 190065 10049502
03 FC:1806 180.00 DA

J:\USF\T144X\PTO\SIDS3.pto.doc/DNB/mv

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of a final action or the notice of allowance. Please charge the fee of \$180.00 to Deposit Account No. 19-0065.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (5 pages); copies of some references cited therein



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/049,502
Filing Date	February 13, 2002
First Named Inventor	Said M. Sebti
Art Unit	1633
Examiner Name	Maria B. Marvich
Attorney Docket Number	USF-T144X

Sheet

1

of

5

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2002-0034725 A1	03-21-2002	McKenna et al.	All
	U2	US-11/274,368	11-14-2005	Sebti (patent application)	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/049,502
				Filing Date	February 13, 2002
				First Named Inventor	Said M. Sebti
				Group Art Unit	1633
				Examiner Name	Maria B. Marvich
				Attorney Docket Number	USF-T144X
Sheet	2	of	5		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ADNANE, J. <i>et al.</i> "Suppression of Rho B expression in invasive carcinoma from head and neck cancer patients" <i>Clin Cancer Res</i> , 2002, 8:2225-2232.	
	R2	ALIMANDI, M. <i>et al.</i> "Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas" <i>Oncogene</i> , 1995, 10:1813-1821.	
	R3	ARBOLEDA, M.J. <i>et al.</i> "Overexpression of AKT2/protein kinase B β leads to up-regulation of β 1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells" <i>Cancer Res</i> , 2003, 63:196-206.	
	R4	BUDAY, L. and DOWNWARD, J. "Epidermal growth factor regulates p21 ^{ras} through the formation of a complex of receptor, Grb2 adaptor protein, and Sos nucleotide exchange factor" <i>Cell</i> , 1993, 73:611-620.	
	R5	DAVIES, M.A. <i>et al.</i> "Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells" <i>Clin Cancer Res</i> , 2002, 8:1904-1914.	
	R6	DU, W. and PRENDERGAST, G.C. "Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors" <i>Cancer Res</i> , 1999, 59:5492-5496.	
	R7	FORGET, M.A. <i>et al.</i> "The expression of Rho proteins decreases with human brain tumor progression: potential tumor markers" <i>Clin Exp Metastasis</i> , 2002, 19(1):9-15, abstract.	
	R8	FRITZ, G. and KAINA, B. " <i>rhoB</i> encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase" <i>J Biol Chem</i> , 1997, 272(49):30637-30644.	
	R9	FRITZ, G. <i>et al.</i> "The Ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments" <i>J Biol Chem</i> , 1995, 270(42):25172-25177.	
	R10	HALL, A. "Rho GTPases and the actin cytoskeleton" <i>Science</i> , 1998, 279(5350):509-514.	
	R11	HUNTER, T. "Oncoprotein networks" <i>Cell</i> , 1997, 88:333-346.	
	R12	JIANG, K. <i>et al.</i> "Regulation of Akt-dependent cell survival by Syk and Rac" <i>Blood</i> , 2003, 101:236-244.	
	R13	KHOSRAVI-FAR, R. and DER, C.J. "The Ras signal transduction pathway" <i>Cancer Metastasis Rev</i> , 1994, 13:67-89.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/049,502
Filing Date	February 13, 2002
First Named Inventor	Said M. Sebti
Group Art Unit	1633
Examiner Name	Maria B. Marvich
Attorney Docket Number	USF-T144X

Sheet	3	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	KIM, D. <i>et al.</i> "Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production" <i>Faseb J</i> , 2001, 15:1953-1962.	
	R15	KUBIATOWSKI, T. <i>et al.</i> "Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas" <i>J Neurosurg</i> , 2001, 95:480-488.	
	R16	LEBOWITZ, P.F. <i>et al.</i> "Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity" <i>Mol Cell Biol</i> , 1995, 15(12):6613-6622.	
	R17	LIU, A. <i>et al.</i> "RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors" <i>Mol Cell Biol</i> , 2000, 20(16):6105-6113.	
	R18	LIU, A. <i>et al.</i> "RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage" <i>Proc Natl Acad Sci USA</i> , 2001, 98(11):6192-6197.	
	R19	LUETTEKE, N.C. <i>et al.</i> "The mouse <i>waved-2</i> phenotype results from a point mutation in the EGF receptor tyrosine kinase" <i>Genes Dev</i> , 1994, 8:399-413.	
	R20	NAKAMURA, T. <i>et al.</i> "Cloning of the RhoB gene from the mouse genome and characterization of its promoter region" <i>Biochem. Biophys. Res. Commun.</i> , 1996, 226(3):688-694, abstract.	
	R21	PARK, B-K. <i>et al.</i> "Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells" <i>Cancer Res</i> , 2001, 61:7647-7653.	
	R22	PRUITT, K. and DER, C.J. "Ras and Rho regulation of the cell cycle and oncogenesis" <i>Cancer Lett.</i> , 2001, 171(1):1-10.	
	R23	QUILLIAM, L.A. <i>et al.</i> "Identification of residues critical for Ras(17N) growth-inhibitory phenotype and for Ras interaction with guanine nucleotide exchange factors" <i>Mol Cell Biol</i> , 1994, 14(2):1113-1121.	
	R24	STEWART, A.L. <i>et al.</i> "PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells" <i>Mol Med</i> , 2002, 8(8):451-461.	
	R25	SYMONS, M. and SETTLEMAN, J. "Rho family GTPases: more than simple switches" <i>Trends Cell Biol</i> , 2000, 10(10):415-419.	
	R26	TURKSON, J. <i>et al.</i> "Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein" <i>Mol Cell Biol</i> , 1999, 19(11):7519-7528.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	10/049,502
			Filing Date	February 13, 2002
			First Named Inventor	Said M. Sebti
			Group Art Unit	1633
			Examiner Name	Maria B. Marvich
			Attorney Docket Number	USF-T144X
Sheet	4	of	5	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	VAN AELST, L. and D'SOUZA-SCHOREY, C. "Rho GTPases and signaling networks" <i>Genes Dev</i> , 1997, 11(18):2295-2322.	
	R28	VLAHOS, C.J. <i>et al.</i> "A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)" <i>J Biol Chem</i> , 1994, 269(7):5241-5248.	
	R29	YANO, H. <i>et al.</i> "Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in FcεRI-mediated signal transduction" <i>Biochem J</i> , 1995, 312(Pt 1):145-150.	
	R30	PENDERGAST and RANE "Farnesyltransferase inhibitors: mechanism and applications" <i>Expert Opin Invest Drugs</i> , 2001, 10(12):2105-2116.	
	R31	ADJEI, A.A. "Ras signaling pathway proteins as therapeutic targets" <i>Curr Pharm Design</i> , 2001, 7:1581-1594.	
	R32	CAPONIGRO, F. "Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy?" <i>Anti-Cancer Drugs</i> , 2002, 13:891-897.	
	R33	END, D.W. <i>et al.</i> "Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 <i>in vivo</i> and <i>in vitro</i> " <i>Cancer Res.</i> , 2001, 61:131-137.	
	R34	GURA, T. "Systems for identifying new drugs are often faulty" <i>Science</i> , 1997, 278:1041-1042.	
	R35	KERBEL, R.S. "Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans" <i>Cancer Biol. & Ther.</i> , 2003, 2(4 Supp. 1):S134-S139.	
	R36	REUTER, C.W. <i>et al.</i> "Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?" <i>Blood</i> , 2000, 96:1655-1669.	
	R37	ROBSON, T. and HIRST, D. "Transcriptional targeting in cancer gene therapy" <i>J. Biomed. Biotech.</i> , 2003, 2:110-137.	
	R38	SHI, B. <i>et al.</i> "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes <i>in vitro</i> and enhances their antitumor activity <i>in vivo</i> " <i>Cancer. Chemother. Pharmacol.</i> , 2000, 46:387-393.	
	R39	VOSKOGLU-NOMIKOS, T. <i>et al.</i> "Clinical predictive value of the <i>in vitro</i> cell line, human xenograft, and mouse allograft preclinical cancer models" <i>Clin. Cancer Res.</i> , 2003, 9:4227-4239.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/049,502
Filing Date	February 13, 2002
First Named Inventor	Said M. Sebti
Group Art Unit	1633
Examiner Name	Maria B. Marvich
Attorney Docket Number	USF-T144X

Sheet 5 of 5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R40	SUN, J. <i>et al.</i> "Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, taxol, and gemcitabine" <i>Cancer Res.</i> , 1999, 59:4919-4926.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.